PAR 2.56% 20.0¢ paradigm biopharmaceuticals limited..

The weird thing is that the Pahase 1 / 2 results and DMOAD study...

  1. 832 Posts.
    lightbulb Created with Sketch. 331
    The weird thing is that the Pahase 1 / 2 results and DMOAD study all back each other up.. So what are we missing?
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.